DE68924478T2 - Prototypische FeLV-Isolate für die Verwendung als Krankheitsmuster oder Impfstoffe. - Google Patents

Prototypische FeLV-Isolate für die Verwendung als Krankheitsmuster oder Impfstoffe.

Info

Publication number
DE68924478T2
DE68924478T2 DE68924478T DE68924478T DE68924478T2 DE 68924478 T2 DE68924478 T2 DE 68924478T2 DE 68924478 T DE68924478 T DE 68924478T DE 68924478 T DE68924478 T DE 68924478T DE 68924478 T2 DE68924478 T2 DE 68924478T2
Authority
DE
Germany
Prior art keywords
vaccines
prototype
isolates
felv
faids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68924478T
Other languages
English (en)
Other versions
DE68924478D1 (de
Inventor
Edward A Hoover
James I Mullins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Colorado State University Research Foundation
Harvard University
Colorado State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Colorado State University Research Foundation, Harvard University, Colorado State University filed Critical Colorado State University Research Foundation
Publication of DE68924478D1 publication Critical patent/DE68924478D1/de
Application granted granted Critical
Publication of DE68924478T2 publication Critical patent/DE68924478T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13061—Methods of inactivation or attenuation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/819—Viral vaccine for feline species, e.g. cats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE68924478T 1988-12-13 1989-12-12 Prototypische FeLV-Isolate für die Verwendung als Krankheitsmuster oder Impfstoffe. Expired - Lifetime DE68924478T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28413988A 1988-12-13 1988-12-13

Publications (2)

Publication Number Publication Date
DE68924478D1 DE68924478D1 (de) 1995-11-09
DE68924478T2 true DE68924478T2 (de) 1996-03-07

Family

ID=23088994

Family Applications (2)

Application Number Title Priority Date Filing Date
DE68924478T Expired - Lifetime DE68924478T2 (de) 1988-12-13 1989-12-12 Prototypische FeLV-Isolate für die Verwendung als Krankheitsmuster oder Impfstoffe.
DE68929419T Expired - Lifetime DE68929419T2 (de) 1988-12-13 1989-12-12 Prototypische FeLV-Isolate für die Verwendung als Krankheitsmuster oder Impfstoff

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE68929419T Expired - Lifetime DE68929419T2 (de) 1988-12-13 1989-12-12 Prototypische FeLV-Isolate für die Verwendung als Krankheitsmuster oder Impfstoff

Country Status (12)

Country Link
US (1) US6042835A (de)
EP (2) EP0699758B1 (de)
JP (1) JP3164351B2 (de)
AT (2) ATE128730T1 (de)
AU (2) AU4616289A (de)
CA (1) CA2005311C (de)
DE (2) DE68924478T2 (de)
DK (1) DK172633B1 (de)
ES (2) ES2084596T3 (de)
GR (1) GR3018587T3 (de)
IE (1) IE74875B1 (de)
NZ (1) NZ231744A (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8901778D0 (en) * 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
IL104382A0 (en) * 1992-01-17 1993-05-13 Solvay Animal Health Inc Vaccine containing acemannan as an adjuvant
GB9210337D0 (en) * 1992-05-14 1992-07-01 Univ Court Of The University O Feline leukaemia virus vaccine
US6013517A (en) 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
JP4303315B2 (ja) 1994-05-09 2009-07-29 オックスフォード バイオメディカ（ユーケー）リミテッド 非交差性レトロウイルスベクター
US7674618B2 (en) 2003-09-04 2010-03-09 Medarex, Inc. Expression vector
ZA200608178B (en) * 2004-03-30 2008-10-29 Roussy Inst Gustave Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins
MX351642B (es) * 2011-07-20 2017-10-23 Merial Ltd Vacuna para virus de leucemia felina recombinante que contiene gen de envoltura del virus de leucemia felina optimizado.
WO2018152097A1 (en) 2017-02-16 2018-08-23 Bio-Rad Laboratories, Inc. Novel reverse transcriptases and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4034081A (en) * 1973-09-18 1977-07-05 University Of Glasgow Vaccines against feline leukemia
GB1486186A (en) * 1973-09-18 1977-09-21 Univ Glasgow Vaccines against feline leukaemia and the group of diseases associated with feline leukaemis/virus infection
US4086134A (en) * 1973-09-18 1978-04-25 University Of Glasgow Method for preparation of vaccine against feline leukemia
US4406885A (en) * 1978-12-28 1983-09-27 Research Corporation Preparation of native oncornavirus envelope subunits and vaccines therefrom
US4264587A (en) * 1979-08-01 1981-04-28 Pedersen Niels C Vaccine for preventing persistent feline leukemia viremia in cats
US4332793A (en) * 1979-12-18 1982-06-01 The Ohio State University Research Foundation Method of recovering cell antigen and preparation of feline leukemia vaccine therefrom
US4434157A (en) * 1979-12-18 1984-02-28 The Ohio State University Research Foundation Method of recovering cell antigen and preparation of feline leukemia vaccine therefrom
US4405712A (en) * 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4593002A (en) * 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
US4701416A (en) * 1983-12-09 1987-10-20 Cetus Corporation Feline leukemia virus vaccine plasmids for fusion protein of the gp70 envelope protein of FELV
EP0156299A3 (de) * 1984-03-26 1987-04-01 Chiron Corporation LTR-modifizierte virale Vakzine
US4663436A (en) * 1984-04-24 1987-05-05 Scripps Clinic And Research Foundation Leukemia-associated virus immunogen, vaccine and assay
US4794168A (en) * 1984-04-24 1988-12-27 Scripps Clinic And Research Foundation Leukemia-associated virus immunogen, vaccine and assay
US4789702A (en) * 1984-05-18 1988-12-06 Cetus Corporation Feline leukemia virus vaccine
US4876089A (en) * 1984-09-06 1989-10-24 Chiron Corporation Feline leukemia virus protein vaccines
US4699785A (en) * 1984-09-18 1987-10-13 The Regents Of The University Of California Cell line producing feline leukemia virus
US4748234A (en) * 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
AU607399B2 (en) * 1985-09-09 1991-03-07 Cetus Corporation Infectious recombinant virus vaccine for feline leukemia
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
PT84976B (pt) * 1986-05-30 1990-02-08 Cambridge Bioscience Corp Metodo para a producao de antigenios de virus de leucemia felina contendo polipeptideos recombinantes
GB2197321B (en) * 1986-09-12 1990-10-03 Genentech Inc Method and vectors for obtaining continuous production of heterologous protein in a eukaryotic host cell line
EP0262887A3 (de) * 1986-10-03 1989-07-26 Bayer Corporation FeLV-infizierter Katzenzellstamm
US5306493A (en) * 1986-10-03 1994-04-26 Miles Inc. FeLV-infected feline cell line
JPH01501939A (ja) * 1987-01-28 1989-07-06 オーソ・フアーマシユーチカル・コーポレーシヨン 免疫抑制ペプチドおよび使用法
AU612404B2 (en) * 1987-09-11 1991-07-11 Genentech Inc. Method for increasing the expression of polypeptides in recombinant cell culture

Also Published As

Publication number Publication date
IE893974L (en) 1990-06-13
IE960745L (en) 1990-06-13
ES2179854T3 (es) 2003-02-01
IE74875B1 (en) 1997-08-13
JP3164351B2 (ja) 2001-05-08
ES2084596T3 (es) 1996-05-16
US6042835A (en) 2000-03-28
DE68924478D1 (de) 1995-11-09
DK631089A (da) 1990-06-14
JPH03117490A (ja) 1991-05-20
GR3018587T3 (en) 1996-04-30
CA2005311C (en) 2006-05-30
ATE221119T1 (de) 2002-08-15
EP0377842A1 (de) 1990-07-18
CA2005311A1 (en) 1990-06-13
DK172633B1 (da) 1999-03-22
EP0699758A1 (de) 1996-03-06
DE68929419T2 (de) 2003-04-03
EP0699758B1 (de) 2002-07-24
AU3710493A (en) 1993-07-15
ATE128730T1 (de) 1995-10-15
DE68929419D1 (de) 2002-08-29
EP0377842B1 (de) 1995-10-04
AU4616289A (en) 1990-06-21
DK631089D0 (da) 1989-12-13
AU661134B2 (en) 1995-07-13
NZ231744A (en) 1993-01-27

Similar Documents

Publication Publication Date Title
DE3782120D1 (de) Asymmetrische gastrennungsmembranen, deren haut einen dichtegradienten aufweisen.
DE3750782T2 (de) Zellinie, die virale Aids-Antigene produziert, ohne infektiöse Viruspartikel zu produzieren.
DE68924478T2 (de) Prototypische FeLV-Isolate für die Verwendung als Krankheitsmuster oder Impfstoffe.
NZ213155A (en) Molecular clones of the genome of hiv (htlv-iii)
PT95093A (pt) Metodos para a culturizacao de hvc em celulas eucarioticas
NZ224581A (en) Hiv-2 peptide, aids vaccine
NZ333431A (en) Multiple epitope fusion protein selected from HIV or HCV, method of immunoassay and assay device
DK520784D0 (da) Cycliske polypeptider, deres fremstilling og anvendelse
ATE91902T1 (de) Hundecoronavirus-impfstoff.
DE3585578D1 (de) Hepatitisoberflaechenantigenpartikelvakzin.
ATE102650T1 (de) Mutanten des infektioesen bovinen rhinotracheitisvirus, vakzine die sie enthalten, verfahren zu ihrer herstellung und ihrer verwendung.
DE68924155T2 (de) Verfahren zur herstellung von natürlichem hiv-glykoprotein 160.
ES2118736T3 (es) Lechadas estables de arcilla calcinada.
DE3763956D1 (de) Falzapparat zur erzeugung von zweimal quergefalzten produkten mit einer hefteinrichtung.
EP0500791A4 (en) The design and construction of non-infectious human retroviral mutants deficient in genomic rna
SU700918A1 (ru) Пьезоэлемент контурных колебаний
SU720759A1 (ru) Устройство дл преобразовани групповых сигналов
ES555123A0 (es) Procedimiento para la formacion de hibridos celulares
JPS642586A (en) Western subtype dna and rna molecule of fsme-virus, polypeptide coded by the molecule and its usage
DE284114T1 (de) Dem lochdorn zugeordneter auswerfer in einer maschine zur herstellung von hohlnieten.
DK0429587T3 (da) Fremgangsmåde til fremstilling af et regulationsprotein af HIV-1 under anvendelse af den humane cellelinie TH4-7-5

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: PRESIDENT AND FELLOWS OF HARVARD COLLEGE, CAMBRIDG

8327 Change in the person/name/address of the patent owner

Owner name: PRESIDENT AND FELLOWS OF HARVARD UNIVERSITY, CAMBR

8364 No opposition during term of opposition